Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of ... special anti-vascular endothelial growth factor agents given by injection into the eye. Dry ... a scientific protocol for the many millions diagnosed with it. AMD usually starts ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... of the winners of the 2015 BeHEARD science challenge, ... that offers rare disease researchers, access to the latest ... use its drug repositioning and pathway analytics capability to ... Wylder Nation Foundation in the study of Niemann-Pick Disease ...
(Date:9/2/2015)... Colo. , Sept. 2, 2015 Aytu ... on developing treatments for urological and related conditions, announced ... its planned private placement convertible note financing, raising a ... prior tranches totaling $3.175 million. ... "Proceeds from this private placement are intended to be ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Fred Alger Management, Inc. (Alger),a leading asset ... M.D. as Vice President, Senior Analyst/Co-Portfolio Manager for,Alger ... and,pharmaceutical industries., David received his Doctor of ... was Chief Medical Resident. While in Pennsylvania David,served ...
... obsolete? EnviroChip™ white papers show how consumers like you can ... damaging your engine. , ... Denver (PRWEB) July 28, ... that EnviroChip™, a revolutionary fuel harmonizing microchip, can eliminate a consumer,s ...
... University of Pennsylvania have created a one-step, repeatable ... or motifs with adjustable features, size and shape ... took advantage of the elastic instability of a ... When exposed to a solvent, circular pores ...
Cached Biology Technology:David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 3
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Sperm whales weigh up to 50 tons, and the smallest ... the same success story: They both have developed the ability ... Now Danish researchers show that the biosonar of toothed ... they live in very different environments and vary extremely in ...
... that glioma is derived from brain tumor stem cells, ... are still unclear. The potential of neural stem cells ... been considered, but has not been confirmed. A team ... Hospital of Nanjing Medical University, China found that doxycycline-induced ...
... active immunization in Alzheimer,s disease can increase the ... but it is easy to induce meningoencephalitis, which ... To enhance anti-Aβ antibody generation and induce a ... from the First Affiliated Hospital of China Medical ...
Cached Biology News:Bats and whales behave in surprisingly similar ways 2Bats and whales behave in surprisingly similar ways 3
... LABTrack provides a familiar interface for ... and warehousing. The transition from paper ... transparent. LABTrack contains an integrated ... and rules mechanism. These functions allow ...
High voltage electrophoresis power supply...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Biology Products: